Key Highlights:
- Hyperfine announced that its AI-powered portable brain MRI device, the Swoop Portable MRI System, has received regulatory approval in India from the Central Drugs Standard Control Organization. The approval enables commercialization of the system across the country, with a commercial launch expected in early 2026.
- The Swoop Portable MRI System is the first FDA-cleared AI-powered portable MRI designed for brain imaging. Compared with conventional MRI systems, it offers portability, lower infrastructure requirements, and improved affordability, enabling hospitals and care centers to perform brain imaging directly at the patient’s bedside.
- In India, Hyperfine will distribute the system through a partnership with Radiosurgery Global, aiming to expand access to neuroimaging for conditions such as stroke, traumatic brain injury, and neurodegenerative diseases in both urban hospitals and remote healthcare settings.
Implications:
The CDSCO approval gives India access to a new category of portable, AI-enabled MRI, which can begin to address the structural gap between neuroimaging demand and limited high-end MRI infrastructure in both public and private settings.
By enabling bedside brain imaging with lower space and power requirements, Swoop can become particularly valuable for stroke, trauma, ICU, and emergency care, where faster triage and monitoring may improve outcomes while avoiding the logistical challenges of transporting unstable patients.
The partnership with Radiosurgery Global provides Hyperfine with an on-ground ally experienced in advanced imaging deployments, increasing the likelihood of uptake in tier-1 and tier-2 hospitals and potentially paving the way for new care models in smaller cities and remote facilities.
Source: Businesswire | Image: Hyperfine
No Comment! Be the first one.